Detalhe da pesquisa
1.
Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.
Ann Rheum Dis
; 80(4): 509-517, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33199274
2.
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.
BMC Musculoskelet Disord
; 18(1): 174, 2017 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28449657
3.
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.
mBio
; 13(6): e0169922, 2022 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36255239
4.
The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Arthritis Rheumatol
; 71(11): 1824-1834, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31207169
5.
Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension.
J Bone Miner Res
; 32(7): 1481-1485, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28277603
6.
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Lancet Diabetes Endocrinol
; 5(7): 513-523, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28546097